Tintillier Michel, Chaput André, Kirch Lotti, Martinet Jean-Paul, Pochet Jean-Michel, Cuvelier Charles
Departments of Internal Medicine and Nephrology, Clinique et Maternité Sainte Elisabeth, Place Godin 15, 5000 Namur, Belgium.
Am J Gastroenterol. 2004 Sep;99(9):1856-8. doi: 10.1111/j.1572-0241.2004.40554.x.
Enteryx (Boston Scientific) is an injectable solution containing 8% ethylene vinyl alcohol copolymer dissolved in dimethyl sulfoxide that has been approved for the treatment of gastroesophageal reflux disease (GERD). The technique consists of injecting Enteryx into the lower esophageal sphincter where it solidifies into a sponge-like permanent implant and prevents or reduces gastric acid reflux into the esophagus. The procedure appears to be generally safe, even if minor or moderate adverse events have been observed. We present the case of a 52-yr-old female treated by Enteryx injection for GERD who developed subsequently an esophageal parietal abscess.
Enteryx（波士顿科学公司生产）是一种注射溶液，含有溶解于二甲基亚砜中的8%乙烯-乙烯醇共聚物，已被批准用于治疗胃食管反流病（GERD）。该技术是将Enteryx注入食管下括约肌，在那里它凝固成海绵状的永久性植入物，防止或减少胃酸反流至食管。该手术总体看来似乎是安全的，尽管已观察到轻微或中度的不良事件。我们报告一例52岁女性，因GERD接受Enteryx注射治疗，随后发生食管壁脓肿。
